NOVAVAX INC (NVAX) FY2025 10-K Annual Report
NOVAVAX INC (NVAX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
NOVAVAX INC FY2025 10-K Analysis
Business Overview
- • Core business model: development and commercialization of vaccines using proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant platform
- • New emphasized partnerships: non-exclusive Matrix-M™ licenses to Pfizer (Jan 2026) and expanded Sanofi agreement for pandemic influenza and COVID-19 combination vaccines
- • Strategic shift: transitioned COVID-19 Vaccine commercialization leadership to Sanofi in 2025; focus on partnerships and licensing over direct commercialization
- • Notable quantitative metric: $0.4 billion remaining obligations under advance purchase agreements; recognized $575.7 million product sales from terminated Canada APA in 2025
- • Noteworthy fact: WHO prequalified the R21/Matrix-M™ adjuvant malaria vaccine in Dec 2023 with rollout in 24 countries as of Feb 2026, marking major commercial expansion beyond COVID-19
Management Discussion & Analysis
- • Revenue $1.12B in 2025, up $441.3M YoY, driven by $685M product sales (+$471.8M) and $438.4M licensing (-$30.5M)
- • Operating expenses $670.7M in 2025 vs $931.1M in 2024; cost of sales 10.7% of product sales vs 95.1% in 2024; R&D $342.3M vs $391.2M; SG&A $157.5M vs $337.2M
- • Net income $440.3M in 2025 vs net loss $187.5M in 2024; operating margin approx. 38.7% ($440.3M net income / $1.12B revenue) vs negative margin prior year
- • Best segment: Product sales $685.0M, +221% YoY; Worst segment: Licensing, royalties, and other $438.4M, -6.5% YoY
- • Cash $750.5M end 2025 vs $938.2M end 2024; Operating cash flow used $244.6M; Issued $225M convertible notes; No dividends or buybacks disclosed
- • Guidance: Expect funding from Sanofi milestones, royalties, product sales, $330M Credit facility available; Risks include regulatory approval delays, APA cancellations (Australia), and capital raising challenges
Risk Factors
- • Regulatory risk: Uncertainty in revenue recognition from licensing agreements under ASC 606 requiring judgment on variable consideration and revenue timing
- • Macroeconomic threat: Exposure to fluctuating interest rates with 4.625% Convertible Senior Notes and variable term loans tied to Term SOFR plus 5.00%
- • Operational risk: Reliance on third-party CMOs and CDMOs for vaccine component manufacturing and raw material procurement, creating supply chain timing and cost estimation challenges
- • Competitive risk: Partnership with Pfizer for Matrix-M adjuvant potentially faces competition in infectious disease vaccines market including influenza-COVID-19 combos by Sanofi
- • Financial risk: $330 million senior secured term loan facility maturing in 2031 with mandatory principal and interest repayment increasing leverage and cash flow obligations
NOVAVAX INC FY2025 Key Financial MetricsXBRL
Revenue
$1.1B
▲ +64.7% YoY
Net Income
$440M
▲ +334.8% YoY
Operating Margin
40.3%
▲ +7679bp YoY
Net Margin
39.2%
▲ +6668bp YoY
ROE
-344.7%
▼ -37471bp YoY
Total Assets
$1.2B
▼ -24.6% YoY
EPS (Diluted)
$2.58
▲ +309.8% YoY
Operating Cash Flow
-$245M
▼ -180.3% YoY
Source: XBRL data from NOVAVAX INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on NOVAVAX INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.